Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Cantor Fitzgerald lowered their FY2021 EPS estimates for shares of Gilead Sciences in a report released on Monday, May 3rd. Cantor Fitzgerald analyst A. Young now expects that the biopharmaceutical company will post earnings of $7.21 per share for the year, down from their prior forecast of $7.38.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.06 by $0.02. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%.
GILD stock opened at $65.80 on Tuesday. The company has a debt-to-equity ratio of 1.65, a quick ratio of 3.15 and a current ratio of 3.25. The firm has a market cap of $82.85 billion, a P/E ratio of 67.84, a PEG ratio of 0.67 and a beta of 0.51. The stock’s 50 day moving average price is $65.14 and its 200 day moving average price is $62.74. Gilead Sciences has a 1 year low of $56.56 and a 1 year high of $81.76.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 29th. Stockholders of record on Tuesday, June 15th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Monday, June 14th. This represents a $2.84 annualized dividend and a dividend yield of 4.32%. Gilead Sciences’s dividend payout ratio is currently 46.25%.
In related news, EVP Brett A. Pletcher sold 1,486 shares of the company’s stock in a transaction on Thursday, March 11th. The stock was sold at an average price of $63.36, for a total transaction of $94,152.96. Following the completion of the transaction, the executive vice president now directly owns 29,166 shares in the company, valued at approximately $1,847,957.76. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Brett A. Pletcher sold 1,975 shares of Gilead Sciences stock in a transaction dated Wednesday, February 10th. The stock was sold at an average price of $67.41, for a total value of $133,134.75. Following the transaction, the executive vice president now directly owns 28,832 shares in the company, valued at $1,943,565.12. The disclosure for this sale can be found here. 0.13% of the stock is owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. Barrett Asset Management LLC raised its stake in shares of Gilead Sciences by 333.0% in the 4th quarter. Barrett Asset Management LLC now owns 433 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 333 shares in the last quarter. TFO TDC LLC acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $26,000. Tortoise Investment Management LLC grew its stake in shares of Gilead Sciences by 81.6% in the fourth quarter. Tortoise Investment Management LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 200 shares in the last quarter. Graves Light Private Wealth Management Inc. bought a new position in Gilead Sciences during the fourth quarter worth $27,000. Finally, Joseph P. Lucia & Associates LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $29,000. Institutional investors and hedge funds own 76.36% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.